4//SEC Filing
Lochner Daniel 4
Accession 0001209191-22-041676
CIK 0001720725other
Filed
Jul 7, 8:00 PM ET
Accepted
Jul 8, 4:55 PM ET
Size
6.1 KB
Accession
0001209191-22-041676
Insider Transaction Report
Form 4
Lochner Daniel
Chief Financial Officer
Transactions
- Award
Performance Stock Units
2022-07-06+300,000→ 300,000 totalExp: 2032-07-05→ Common Stock (300,000 underlying)
Footnotes (2)
- [F1]Represents a grant of performance stock units (the "PSUs"). Each PSU represents a contingent right to receive one share of Common Stock of the Issuer.
- [F2]The PSUs will vest as to (i) 50% on July 6, 2023; and (ii) 50% at such time, if any, beginning on July 6, 2023 and ending on July 6, 2024, the 30 day volume-weighted average stock price reaches $6.00 per share (the "VWAP Vesting Period"), subject to the Reporting Person's continuous service to the Issuer through each such date. For clarity, the applicable thirty (30) consecutive day period must occur entirely during the VWAP Vesting Period and the thirty (30) day volume-weighted average stock price will be measured during any thirty (30) consecutive trading days during such VWAP Vesting Period.
Documents
Issuer
Oyster Point Pharma, Inc.
CIK 0001720725
Entity typeother
Related Parties
1- filerCIK 0001791187
Filing Metadata
- Form type
- 4
- Filed
- Jul 7, 8:00 PM ET
- Accepted
- Jul 8, 4:55 PM ET
- Size
- 6.1 KB